Showing results (281-290 of 463) with videos related to

Sort By:
Pageof 47
Expert Review of Neurotherapeutics|August 7, 2020
'Dopamine agonist Phobia' in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicineSilvia Rota, Iro Boura, Lucia Batzu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's diseaseRupam Borgohain, Jozsef Szasz, Paolo Stanzione, et al.
British Journal of Clinical Pharmacology|August 6, 2019
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar)Margherita Torti, Jhessica Alessandroni, Daniele Bravi, et al.
Plos One|October 16, 2015
Acute Modulation of Brain Connectivity in Parkinson Disease after Automatic Mechanical Peripheral Stimulation: A Pilot StudyCarlo Cosimo Quattrocchi, Maria Francesca de Pandis, Claudia Piervincenzi, et al.
Neurology|May 12, 2017
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson diseaseFabrizio Stocchi, Olivier Rascol, Robert A Hauser, et al.
Neuroreport|August 9, 2002
Proteasome inhibition causes nigral degeneration with inclusion bodies in ratsKevin St P McNaught, Lars M Björklund, Roger Belizaire, et al.
The Journal of Biological Chemistry|May 30, 2002
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasomeDong-Hoon Hyun, MoonHee Lee, Nobutaka Hattori, et al.
The European Journal of Neuroscience|July 28, 2005
The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activationMahmoud M Iravani, Clement C M Leung, Mona Sadeghian, et al.
Behavioural Pharmacology|March 14, 2007
Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primatesSarah Rose, Dieter K A Scheller, Alexander Breidenbach, et al.
European Journal of Pharmacology|September 30, 2015
The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosetsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, et al.
Pageof 47